Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients-Reference-Cited by-同舟云学术

Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients

Published:2018-09-21 Issue:4 Volume:4 Page:262-273
ISSN:2056-4538
Container-title:The Journal of Pathology: Clinical Research
language:en
Short-container-title:J Pathol Clin Res

Author:

Dodson Andrew¹²^ORCID,Parry Suzanne³,Ibrahim Merdol³,Bartlett John MS⁴,Pinder Sarah⁵,Dowsett Mitch¹²,Miller Keith³

Affiliation:

1. Ralph Lauren Centre for Breast Cancer Research; The Royal Marsden Hospital; London UK

2. The Institute of Cancer Research; London UK

3. UK NEQAS ICC & ISH; University College London Cancer Institute; London UK

4. Ontario Institute for Cancer Research; Ontario Canada

5. Cancer Studies, King's College London; London UK

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cjp2.112/fullpdf

Reference12 articles.

1. UK-NEQAS ICC & ISH www.ukneqasiccish.org

2. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy;Bartlett;J Clin Oncol,2007

3. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer;Kaufman;Cancer,2014

4. Updated UK recommendations for HER2 assessment in breast cancer;Rakha;J Clin Pathol,2015

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2‐positive grade 1 invasive carcinomas of the breast;Histopathology;2024-09-11

2. Clinical Outcomes and Efficacy of Human Epidermal Growth Factor Receptor 2–Targeted Therapy in Breast Cancer With Uncommon In Situ Hybridization Patterns or Discordant Immunohistochemistry;JCO Oncology Advances;2024-09

3. Deciphering the Clinical Behaviour of Invasive Lobular Carcinoma of the Breast Defines an Aggressive Subtype;Cancers;2024-05-16

4. Association Between Polymorphisms of NRF2 and Breast Cancer Risk in Japanese Population;Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics;2024-03-31

5. Exploring the Spatial Landscape of the Estrogen Receptor Proximal Proteome With Antibody-Based Proximity Labeling;Molecular & Cellular Proteomics;2024-01